Biotechnology will have a strong year in 2015, but it can’t get any better than 2014, biotech investor G. Steven Burrill says in his annual year-end report.
“The unprecedented IPO (initial public offering) and M&A (mergers and acquisitions) activity this year will make 2014 one for the record books and unlikely to ever be surpassed,” Burrill said.